ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers

被引:53
作者
Rebocho, A. P. [1 ]
Marais, R. [1 ]
机构
[1] Inst Canc Res, Div Canc Biol, Signal Transduct Team, London SW3 6JB, England
关键词
ARAF; BRAF; CRAF; protein complexes; paradoxical activation; B-RAF; C-RAF; HUMAN CANCER; WILD-TYPE; KINASE-ACTIVITY; ONCOGENIC RAS; MUTATIONS; MELANOMA; PHOSPHORYLATION; ACTIVATION;
D O I
10.1038/onc.2012.330
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The RAF proteins are cytosolic protein kinases that regulate cell responses to extracellular signals. There are three RAF proteins in cells, ARAF, BRAF and CRAF, and recent studies have shown that the formation of complexes by these different isoforms has an important role in their activation, particularly in response to RAF inhibitors. Here, we investigated the role of ARAF in cancer cell signaling and examined the role of ARAF in mediating paradoxical activation of the MAPK pathway in cells treated with RAF inhibitors. We show that two mutations that occur in ARAF in cancer inactivate the kinase. We also show that ARAF is not functionally redundant with CRAF and cannot substitute for CRAF downstream of RAS. We further show that ARAF binds to and is activated by BRAF and that ARAF also forms complexes with CRAF. Critically, ARAF seems to stabilize BRAF: CRAF complexes in cells treated with RAF inhibitors and thereby regulate cell signaling in a subtle manner to ensure signaling efficiency.
引用
收藏
页码:3207 / 3212
页数:6
相关论文
共 28 条
[1]   c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma [J].
Blasco, Rafael B. ;
Francoz, Sarah ;
Santamaria, David ;
Canamero, Marta ;
Dubus, Pierre ;
Charron, Jean ;
Baccarini, Manuela ;
Barbacid, Mariano .
CANCER CELL, 2011, 19 (05) :652-663
[2]   Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].
Bollag, Gideon ;
Hirth, Peter ;
Tsai, James ;
Zhang, Jiazhong ;
Ibrahim, Prabha N. ;
Cho, Hanna ;
Spevak, Wayne ;
Zhang, Chao ;
Zhang, Ying ;
Habets, Gaston ;
Burton, ElizabethA. ;
Wong, Bernice ;
Tsang, Garson ;
West, Brian L. ;
Powell, Ben ;
Shellooe, Rafe ;
Marimuthu, Adhirai ;
Nguyen, Hoa ;
Zhang, Kam Y. J. ;
Artis, Dean R. ;
Schlessinger, Joseph ;
Su, Fei ;
Higgins, Brian ;
Iyer, Raman ;
D'Andrea, Kurt ;
Koehler, Astrid ;
Stumm, Michael ;
Lin, Paul S. ;
Lee, Richard J. ;
Grippo, Joseph ;
Puzanov, Igor ;
Kim, Kevin B. ;
Ribas, Antoni ;
McArthur, Grant A. ;
Sosman, Jeffrey A. ;
Chapman, Paul B. ;
Flaherty, Keith T. ;
Xu, Xiaowei ;
Nathanson, Katherine L. ;
Nolop, Keith .
NATURE, 2010, 467 (7315) :596-599
[3]   Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].
Chapman, Paul B. ;
Hauschild, Axel ;
Robert, Caroline ;
Haanen, John B. ;
Ascierto, Paolo ;
Larkin, James ;
Dummer, Reinhard ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Hogg, David ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
Ribas, Antoni ;
O'Day, Steven J. ;
Sosman, Jeffrey A. ;
Kirkwood, John M. ;
Eggermont, Alexander M. M. ;
Dreno, Brigitte ;
Nolop, Keith ;
Li, Jiang ;
Nelson, Betty ;
Hou, Jeannie ;
Lee, Richard J. ;
Flaherty, Keith T. ;
McArthur, Grant A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516
[4]   Positive and negative regulation of Raf kinase activity and function by phosphorylation [J].
Chong, H ;
Lee, J ;
Guan, KL .
EMBO JOURNAL, 2001, 20 (14) :3716-3727
[5]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[6]   New insight into BRAF mutations in cancer [J].
Dhomen, Nathalie ;
Marais, Richard .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2007, 17 (01) :31-39
[7]   In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling [J].
Dumaz, Nicolas ;
Hayward, Robert ;
Martin, Jan ;
Ogilvie, Lesley ;
Hedley, Douglas ;
Curtin, John A. ;
Bastian, Boris C. ;
Springer, Caroline ;
Marais, Richard .
CANCER RESEARCH, 2006, 66 (19) :9483-9491
[8]   Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF [J].
Emuss, V ;
Garnett, M ;
Mason, C ;
Marais, R .
CANCER RESEARCH, 2005, 65 (21) :9719-9726
[9]   Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].
Flaherty, Keith T. ;
Puzanov, Igor ;
Kim, Kevin B. ;
Ribas, Antoni ;
McArthur, Grant A. ;
Sosman, Jeffrey A. ;
O'Dwyer, Peter J. ;
Lee, Richard J. ;
Grippo, Joseph F. ;
Nolop, Keith ;
Chapman, Paul B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819
[10]   Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization [J].
Garnett, MJ ;
Rana, S ;
Paterson, H ;
Barford, D ;
Marais, R .
MOLECULAR CELL, 2005, 20 (06) :963-969